Completing the toxicology program with these positive results is a major milestone for Pharmability. The data show that our drug candidate is well tolerated even at high exposure levels and, importantly, that systemic exposure is minimal following cutaneous administration. This strengthens the safety profile of cutaneous TIR-C treatment as we prepare for the Phase Ib study in atopic dermatitis.

We are very pleased to welcome Agneta to Pharmability. Her extensive experience in clinical project management and early-phase development strengthens our capacity as we advance TIR-C into its next stage of development and continue building a strong and experienced project team.

Pharmability marks a new chapter for the company. The name captures our ambition to translate immunological research into new therapies and create value for patients as we enter the next phase.

This publication provides important mechanistic insight into how TIR-01 interacts with early myeloid differentiation and promotes the development of tolerogenic dendritic cells. The data strengthen the scientific rationale behind our immunomodulatory strategy and support the continued advancement of our development program toward clinical studies.

The collaboration with Bachem is an important milestone in our efforts to advance our candidate drug to the clinic. Through this collaboration, we gain access to world-leading manufacturing expertise and strengthen the foundation for offering patients a more durable treatment option

The expanded partnership with Zelmic marks a milestone in the clinical development of TIR-C. Zelmic’s deep expertise in topical formulation development strengthens the foundation for our clinical program and supports our mission to improve treatment outcomes for patients with atopic dermatitis worldwide.

These are the final safety studies before entering the clinic – a critical milestone in our development program. ERBC’s experience with this type of study makes them a valuable partner, and with their support, we are confident in generating the data needed to move into Phase I next year.

We are very pleased to welcome Peder Walberg and Christian Krog-Jensen to the board. Their complementary expertise in clinical development, strategic planning, and financing will be essential as we bring TIR-C into the clinic and position the company for long-term success

Bringing TIR-C into the clinic is a major milestone for us – and it demands the right team. Elisabeth brings not only extensive experience, but also the strategic mindset we need at this stage. Her contributions will be essential as we move through the regulatory process and prepare for clinical execution.

This capital injection enables us to take the decisive step into clinical development and move closer to a future where patients have access to more durable and effective treatment. The strong support from Sciety and their investor network gives us both the momentum and the means to accelerate our development.